Compass Capital Management Inc. Increases Position in Stryker Corporation $SYK

Compass Capital Management Inc. increased its holdings in Stryker Corporation (NYSE:SYK) by 3.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 160,479 shares of the medical technology company’s stock after buying an additional 5,301 shares during the period. Stryker comprises about 3.0% of Compass Capital Management Inc.’s holdings, making the stock its 16th biggest position. Compass Capital Management Inc.’s holdings in Stryker were worth $50,525,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. VanderPol Investments L.L.C. grew its stake in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC boosted its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after buying an additional 28 shares during the last quarter. Tcfg Wealth Management LLC grew its position in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, West Michigan Advisors LLC grew its position in Stryker by 0.4% during the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock valued at $2,631,000 after buying an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Needham & Company LLC dropped their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. BMO Capital Markets assumed coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. Royal Bank Of Canada lowered their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Finally, Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

Shares of NYSE:SYK opened at $338.80 on Monday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The company has a 50-day moving average price of $324.61 and a two-hundred day moving average price of $333.40.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.